Y-mAbs Therapeutics (YMAB) Competitor Comparison
We are evaluating the key criteria listed to compare Y-mAbs Therapeutics (YMAB) against its competitors in the Biotechnology industry.
Market Capitalization
149 / 368Gross Profits
59 / 278Total Revenue
94 / 300EBITDA
75 / 337Free Cashflow
87 / 352Quick Ratio
189 / 357Earnings per Share
90 / 359Dividend yield
0 / 6Total Cash
228 / 358Performance 3 years
160 / 368Performance 5 years
214 / 368Performance 10 years
171 / 368Linearity 3 years
114 / 368Linearity 5 years
166 / 368Linearity 10 years
93 / 367Total Rank
74 / 368Dividend Rank
317 / 368Valuation Rank
28 / 368Piotroski Rank
200 / 368Muliplier Rank
244 / 368Market Capitalization - YMAB ranking 149 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.